Document Detail


Management of von Willebrand disease in developing countries.
MedLine Citation:
PMID:  16276468     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A variety of treatment options are available at present for patients with von Willebrand disease (vWD), some of which are affordable for patients in developing countries. For most patients who have type 1 vWD, desmopressin acetate (DDAVP) is the treatment of first choice, at least for minor bleedings and for prophylaxis. It is advisable, however, to use a test dose first to note the patient's response. DDAVP is safe to use, affordable, and easy to administer. However, most patients with type 2 vWD and all patients with type 3 fail to respond to DDAVP. For these patients, other options are used. Almost all patients with vWD will benefit from fresh frozen plasma and from cryoprecipitate, and these are viable options for developing countries. Both have certain disadvantages, but they can, depending upon the circumstances and facilities, be produced in developing countries. In developed countries, factor VIII/von Willebrand factor concentrates are widely used, especially for major bleedings and for surgeries on these patients. These concentrates are safe and virus inactivated, but costly. Ancillary treatment modalities such as antifibrinolytic agents and certain hormones are usually given in conjunction with other modalities. The treatment of patients with antibodies to vWF is also described, and monitoring needs during therapy are reviewed.
Authors:
Pier M Mannucci
Related Documents :
18452978 - Chronic viral hepatitis c, oxidative stress and the coagulation/fibrinolysis system in ...
22718018 - Subtelomeric deletions of 1q43q44 and severe brain impairment associated with delayed m...
10461428 - The imbalance between coagulation and fibrinolysis is related to the severity of the il...
18078398 - Inhibitors in haemophilia a: current management and open issues.
8322838 - Renal biopsy in the elderly.
23776388 - Treatment of confirmed b12 deficiency in hemodialysis patients improves epogen® requir...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in thrombosis and hemostasis     Volume:  31     ISSN:  0094-6176     ISO Abbreviation:  Semin. Thromb. Hemost.     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-11-08     Completed Date:  2005-12-29     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0431155     Medline TA:  Semin Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  602-9     Citation Subset:  IM    
Affiliation:
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Department of Internal Medicine and Dermatology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy. pmmannucci@libero.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Coagulation Factors / therapeutic use
Chemotherapy, Adjuvant
Deamino Arginine Vasopressin / therapeutic use
Developing Countries* / economics
Disease Management
Hemorrhage / drug therapy,  prevention & control
Humans
Practice Guidelines as Topic
Treatment Outcome
von Willebrand Diseases / economics,  therapy*
Chemical
Reg. No./Substance:
0/Blood Coagulation Factors; 16679-58-6/Deamino Arginine Vasopressin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of ...
Next Document:  Geriatric urology -- incontinence in the elderly